Table 1 Clinicodemographic patient characteristics
Factor | N (%) |
|---|---|
Gender (n) | |
Male | 27 (40.30%) |
Female | 40 (59.70%) |
Age (median, range) (y) | 53.01 (36.73–78.35) |
Smoking history (n) | |
No | 50 (74.63%) |
Yes | 17 (25.37%) |
T stage in naïve (n) | |
1–2 | 43 (64.18%) |
3–4 | 24 (35.82%) |
TNM stage (n) | |
IIIB-IIIC | 13 (19.40%) |
IVA-IVB | 54 (80.60%) |
Location (n) | |
Upper lobe | 21 (31.34%) |
Middle and lower lobe | 46 (68.66%) |
Type of mutation (n) | |
EGFR exon 19 del | 30 (44.78%) |
EGFR exon 21 L858R | 29 (43.28%) |
Others | 8 (11.94%) |
Type of EGFR-TKI (n) | |
Gefitinib | 39 (58.21%) |
Erlotinib | 17 (25.37%) |
Icotinib | 11 (16.42%) |
The treatment model (n) | |
Simultaneous EGFR-TKI and TRT for first line | 16 (23.88%) |
Simultaneous EGFR-TKI, chemotherapy and TRT for first line | 18 (26.87%) |
Previous chemotherapy, simultaneous EGFR-TKI and TRT for second line | 33 (49.25%) |
Dose fractionation (n) | |
CFRT | 59 (88.06%) |
SBRT | 8 (11.94%) |
Dose per fraction (median, range) (Gy) | 2 (2–12) |
Total dose (median, range) (Gy) | 56 (39–72) |
GTV (median, range) (ml) | 25.30 (0.70–338.80) |
PTV (median, range) (ml) | 133.30 (11.40–752.20) |